0001437749-24-022188.txt : 20240703 0001437749-24-022188.hdr.sgml : 20240703 20240703163224 ACCESSION NUMBER: 0001437749-24-022188 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240628 ITEM INFORMATION: Termination of a Material Definitive Agreement ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240703 DATE AS OF CHANGE: 20240703 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PIERIS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001583648 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 300784346 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37471 FILM NUMBER: 241100541 BUSINESS ADDRESS: STREET 1: 225 FRANKLIN STREET STREET 2: 26TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 857-246-8998 MAIL ADDRESS: STREET 1: 225 FRANKLIN STREET STREET 2: 26TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 FORMER COMPANY: FORMER CONFORMED NAME: Marika Inc. DATE OF NAME CHANGE: 20130805 8-K 1 pirs20240612_8k.htm FORM 8-K pirs20240612_8k.htm
false 0001583648 0001583648 2024-06-28 2024-06-28
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): June 28, 2024
 
PIERIS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
 
 
Nevada
001-37471
30-0784346
(State or other jurisdiction of
Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
 
225 Franklin Street, 26th Floor
02110
Boston, MA
  
(Address of principal executive offices)
(Zip Code)
 
Registrant’s telephone number, including area code: 857-246-8998
N/A
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
  
Trading Symbol(s)
  
Name of each exchange on which registered
Common Stock, $0.001 par value per share
  
PIRS
  
The Nasdaq Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
 
Emerging Growth Company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
 
 
 
 
Item 1.02 Termination of a Material Definitive Agreement
 
On June 28, 2024, Les Laboratoires Servier and Institut de Recherches Internationales Servier (collectively, "Servier"), provided Pieris Pharmaceuticals, Inc. (the "Company") with a written notice of termination of the License and Collaboration Agreement between Servier, the Company, and Pieris Pharmaceuticals GmbH, dated January 4, 2017, and subsequently amended (the "Collaboration Agreement"). Pursuant to Section 7.1 of the Non-Exclusive Anticalin® Platform Technology License Agreement, between Servier, the Company, and Pieris Pharmaceuticals GmbH, dated January 4, 2017 (the "Non-Exclusive License Agreement"), the Non-Exclusive License Agreement terminates upon termination of the Collaboration Agreement. The Collaboration Agreement and Non-Exclusive License Agreement (collectively, the "Agreements") will terminate effective December 27, 2024, or 180 days from the date on which Servier notified the Company of its intent to terminate the Agreements. 
 
Pursuant to the Agreements, Servier and the Company agreed to collaborate on the research, development, and commercialization of Anticalin-based therapeutics as part of the Company's immuno-oncology franchise, including S095012 (formerly, PRS-344), a 4-1BB/PD-L1 bispecific Mabcalin® protein that was being developed worldwide by Servier. With this notice, Servier will discontinue and cease dosing in the Phase 1 clinical study of S095012. Servier's decision to terminate the Agreements was based on a potential safety concern in the S095012 Phase 1 clinical studies. The Company intends to review the safety data from the S095012 Phase 1 clinical study to understand the implications of the data. The Company does not intend to pursue any further development of S095012.
 
The foregoing is only a summary of the material terms of the Agreements, does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreements, which were filed as Exhibits 10.15 and 10.16 to the Company’s Annual Report, as amended, on Form 10-K/A (File No. 001-37471) with the Securities and Exchange Commission (the “SEC”) on April 26, 2018; the First Amendment, dated as of June 16, 2017, to the Collaboration Agreement, which was filed as Exhibit 10.4 to the Company’s Quarterly Report, as amended, on Form 10-Q/A (File No. 001-37471) with the SEC on April 26, 2018; and the Letter Amendment, dated as of January 3, 2020, to the Collaboration Agreement, which was filed as Exhibit 10.16 to the Company’s Annual Report on Form 10-K (File No. 001-37471) with the SEC on March 13, 2020.
 
 
 
 
Item 8.01 Other Events.
 
As announced on March 27, 2024, the Company implemented a strategy to maximize its ability to capture the potential milestones from its partnered 4-1BB bispecific Mabcalin (antibody-Anticalin fusion) protein immuno-oncology assets, while also maintaining the capability to consider strategic opportunities that it believes may increase stockholder value. The Company continues to remain eligible to receive potential milestone and royalty payments across its remaining partnered 4-1BB bispecific Mabcalin protein franchise resulting from its partnerships with Boston Pharmaceuticals and Pfizer, Inc. (formerly Seagen). This includes potential aggregate milestones of up to $15 million upon first patient dosed in the Phase 2 trials for SGN-BB228 and BOS-342, which are currently in Phase 1 clinical development, potential aggregate milestones of up to $40 million upon first patient dosed in pivotal clinical trials for SGN-BB228 and BOS-342, and total development milestone potential from the two clinical stage assets in single, primary indications could be up to $200 million. Total commercial milestone potential on the same assets, if they are approved, could amount to more than $415 million. A potential additional aggregate amount of up to $130 million in both developmental and commercial milestones exists if these programs are developed in additional indications.
 
Forward Looking Statements
 
This Current Report on Form 8-K, or Form 8-K, contains forward looking statements. Statements in this Form 8-K that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things statements relating to potentially considering strategic opportunities; anticipated timing, achievement, and receipt of milestone and/or royalty payments provided for in the Company's collaboration agreements; discontinuing development of S095012; the potential size of potential milestones and royalties; and the possible monetization of milestones and royalties. Actual results could differ from those projected in any forward-looking statement due to numerous factors. Such factors include, among others, expectations for achievement of contractual milestones; availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses; the Company's cash runway may be reduced by unanticipated liabilities or decisions to opportunistically pursue strategic opportunities; the Company's ability to be successful in exploring and consummating one or more licensing or other transactions on attractive terms if at all for the Company's products in prior development; the Company's ability to maintain a lean and capable management team and board of directors over time; the Company's actual reductions in spending as compared to anticipated cost reductions; including in collaboration with other parties, the inherent uncertainties associated with developing new products or technologies, such as Anticalin based compounds, the Company's partners’ ability to develop, complete clinical trials for, obtain approvals for and commercialize any of the Company's partnered product candidates; the Company's partners' ability to achieve expected market share if the drugs are approved and commercialized; uncertainty of overall market size of any of the Company’s partnered product candidates; competition in the industry in which the Company operates; the possibility that the Company’s partners may decide not to prioritize or further pursue the programs that the Company hopes to receive milestone and royalty payments under; the fact that data and results from clinical studies may not necessarily be indicative of future results; the Company may face challenges in continuing to comply with the listing standards of The Nasdaq Stock Market LLC, such as those relating to operating company status; delays or disruptions due to geopolitical issues, including the conflicts in Ukraine and the Middle East; and overall market conditions. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosures set forth in the reports and other documents the Company files with the Securities and Exchange Commission, or the SEC, available at www.sec.gov, including, without limitation, the Company’s most recent Annual Report on Form 10-K, as amended, the Company’s Quarterly Reports on Form 10-Q, and subsequent filings with the SEC.
 
 
 
 
Item 9.01 Financial Statements and Exhibits.
 
(d) Exhibits.
 
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
 
 
 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
PIERIS PHARMACEUTICALS, INC.
   
Dated: July 3, 2024
/s/ Tom Bures
 
Tom Bures
 
Chief Financial Officer
 
 
 
 
 EX-101.SCH 2 pirs-20240628.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 3 pirs-20240628_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 4 pirs-20240628_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, Postal Zip Code Entity, Address, City or Town Entity, Address, State or Province City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key EX-101.PRE 5 pirs-20240628_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.2
Document And Entity Information
Jun. 28, 2024
Document Information [Line Items]  
Entity, Registrant Name PIERIS PHARMACEUTICALS, INC.
Document, Type 8-K
Document, Period End Date Jun. 28, 2024
Entity, Incorporation, State or Country Code NV
Entity, File Number 001-37471
Entity, Tax Identification Number 30-0784346
Entity, Address, Address Line One 225 Franklin Street, 26th Floor
Entity, Address, Postal Zip Code 02110
Entity, Address, City or Town Boston
Entity, Address, State or Province MA
City Area Code 857
Local Phone Number 246-8998
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol PIRS
Security Exchange Name NASDAQ
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0001583648
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2 html 1 22 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.pirs.com/20240628/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports pirs-20240628.xsd pirs-20240628_def.xml pirs-20240628_lab.xml pirs-20240628_pre.xml pirs20240612_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "pirs20240612_8k.htm": { "nsprefix": "pirs", "nsuri": "http://www.pirs.com/20240628", "dts": { "schema": { "local": [ "pirs-20240628.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "definitionLink": { "local": [ "pirs-20240628_def.xml" ] }, "labelLink": { "local": [ "pirs-20240628_lab.xml" ] }, "presentationLink": { "local": [ "pirs-20240628_pre.xml" ] }, "inline": { "local": [ "pirs20240612_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 26, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.pirs.com/20240628/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d20248K", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pirs20240612_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d20248K", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pirs20240612_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.pirs.com/20240628/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.pirs.com/20240628/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.pirs.com/20240628/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.pirs.com/20240628/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.pirs.com/20240628/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.pirs.com/20240628/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.pirs.com/20240628/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.pirs.com/20240628/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.pirs.com/20240628/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.pirs.com/20240628/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.pirs.com/20240628/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.pirs.com/20240628/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.pirs.com/20240628/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.pirs.com/20240628/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.pirs.com/20240628/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.pirs.com/20240628/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.pirs.com/20240628/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.pirs.com/20240628/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.pirs.com/20240628/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.pirs.com/20240628/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.pirs.com/20240628/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.pirs.com/20240628/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.pirs.com/20240628/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.pirs.com/20240628/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.pirs.com/20240628/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001437749-24-022188-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-24-022188-xbrl.zip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pirs20240612_8k_htm.xml IDEA: XBRL DOCUMENT 0001583648 2024-06-28 2024-06-28 false 0001583648 8-K 2024-06-28 PIERIS PHARMACEUTICALS, INC. NV 001-37471 30-0784346 225 Franklin Street, 26th Floor 02110 Boston MA 857 246-8998 false false false false Common Stock PIRS NASDAQ false